Depo-Provera Lawsuit Update: June 2026 Filings Surge 46% in a Single Month
The Depo-Provera meningioma litigation (MDL-3140) just posted its biggest one-month jump on record. The June 2026 JPML report shows 5,508 pending cases — up 1,739 from May, a single-month surge larger than the entire prior-record month and a sign that the brain-tumor docket is accelerating into a pivotal summer.
Key Takeaways
- Depo-Provera (MDL-3140) grew from 3,769 to 5,508 pending cases in June 2026 — a record +1,739 in one month
- June's gain eclipsed the prior single-month record of +1,001 set in March 2026
- The surge accounted for more than 70% of the entire federal MDL system's net growth this month
- A 3-day general-causation Daubert hearing is set for June 24-26, 2026, with Judge Rodgers' federal-preemption ruling still pending
- The first bellwether trial (Blonski v. Pfizer) remains scheduled for December 7, 2026
When the Judicial Panel on Multidistrict Litigation released its June 1, 2026 statistics report, one number stood out across the entire federal docket. The Depo-Provera meningioma MDL, consolidated before Judge M. Casey Rodgers in the Northern District of Florida, added 1,739 pending cases in a single month — vaulting from 3,769 in May to 5,508 in June and climbing from 11th to 9th among the largest active MDLs in the country.
To put the move in context: across all 159 active MDLs, the system added roughly 2,445 net pending actions in June. Depo-Provera alone was responsible for more than seven of every ten of those new cases. It is the kind of month-over-month acceleration that typically precedes a major procedural milestone — and that milestone is now days away.
Pending Cases Over Time
MDL-3140 pending actions by month, from the docket's creation in early 2025 through June 2026. The June reading is a new high.
Source: JPML MDL Statistics Reports, March 2025 – June 2026.
New Cases Added Each Month
Net change in pending actions month over month. June 2026's +1,739 is the tallest bar on the chart — surpassing the previous record set in March 2026.
Source: month-over-month differences in JPML pending-action counts.
What's driving the June spike?
Filing surges of this size rarely happen in isolation. Two converging catalysts help explain why thousands of plaintiffs moved to get into the MDL now rather than later:
- ▸ The FDA's December 2025 meningioma label change. The agency's addition of a meningioma warning to Depo-Provera's prescribing information continues to reverberate, prompting newly aware patients and their attorneys to file ahead of looming case-management deadlines.
- ▸ A pivotal Daubert hearing on the calendar. Plaintiffs' firms have an incentive to consolidate clients into the federal MDL before the general-causation expert fight is decided — a ruling that could reshape the litigation's trajectory for everyone already in it.
Recent Developments at a Glance
What to watch next
The near-term story is the June 24-26 Daubert hearing, where Judge Rodgers will weigh whether plaintiffs' general-causation experts can testify that Depo-Provera causes meningioma. Running in parallel is Pfizer's federal-preemption motion under PTO 30 — a decision that would apply to every case in the MDL and has not yet issued. Either ruling could meaningfully change the pace of new filings in the months ahead.
If the current trajectory holds, the docket could approach or exceed the next round-number milestone before the December bellwether. We update these figures every month as soon as the JPML publishes its report.
Looking for the full case overview or to check your eligibility?
This page tracks the latest movement in the litigation. For the complete Depo-Provera lawsuit background — who qualifies, the science linking the contraceptive to meningioma, settlement outlook, and how to join — visit our dedicated case hub.
Sources
- • U.S. Judicial Panel on Multidistrict Litigation — Distribution of Pending MDL Dockets by Actions Pending (May 1 & June 1, 2026 reports).
- • U.S. District Court, Northern District of Florida — MDL-3140 docket, PTO 30 and pretrial scheduling orders.
- • U.S. Food & Drug Administration — December 2025 Depo-Provera labeling update.
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.